Yoo Jin Jung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoo Jin Jung has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Ahreum Kim
SKKU Advanced Institute of Nanotechnology (SAINT)
3 shared publications - Chang Hyun Kang
Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul, Republic of Korea
3 shared publications - Hyunjoo Lee
Department of Pediatrics, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
3 shared publications - In-Kyu Park
Department of Biomedical Sciences and BioMedical Sciences Graduate Program (BMSGP), Chonnam National University Medical School, Hwasun, Republic of Korea
3 shared publications - Jeong-Sun Seo
Precision Medicine Center, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea
3 shared publications - Ji Won Lee
Gangneung-Wonju National University 2 Department of Biology Gangneung 25457
3 shared publications
Latest Publications
- Top Cited Papers
- 23 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 385 (6711) , eabm6131
Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies
Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer’s disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indoleamine-2,3-dioxygenase 1 (IDO1), which metabolizes tryptophan to kynurenine (KYN), rescues hippocampal memory function in mouse preclinical models of AD by restoring astrocyte metabolism. Activation of astrocytic IDO1 by amyloid β and tau oligomers increases KYN and suppresses glycolysis in an aryl hydrocarbon receptor–dependent manner. In amyloid and tau models, IDO1 inhibition improves hippocampal glucose metabolism and rescues hippocampal long-term potentiation in a monocarboxylate transporter–dependent manner. In astrocytic and neuronal cocultures from AD subjects, IDO1 inhibition improved astrocytic production of lactate and uptake by neurons. Thus, IDO1 inhibitors presently developed for cancer might be repurposed for treatment of AD.
- 23 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 385 (6711) , eabm6131
Top Cited PapersRestoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies
Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer’s disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indoleamine-2,3-dioxygenase 1 (IDO1), which metabolizes tryptophan to kynurenine (KYN), rescues hippocampal memory function in mouse preclinical models of AD by restoring astrocyte metabolism. Activation of astrocytic IDO1 by amyloid β and tau oligomers increases KYN and suppresses glycolysis in an aryl hydrocarbon receptor–dependent manner. In amyloid and tau models, IDO1 inhibition improves hippocampal glucose metabolism and rescues hippocampal long-term potentiation in a monocarboxylate transporter–dependent manner. In astrocytic and neuronal cocultures from AD subjects, IDO1 inhibition improved astrocytic production of lactate and uptake by neurons. Thus, IDO1 inhibitors presently developed for cancer might be repurposed for treatment of AD.
- Open Access
- 26 October 2023
- Published by Open Exploration Publishing
- Vol. 3 (5) , 281-298
The effects of post-translational modifications on alpha-synuclein aggregation and immune cell activation in Parkinson’s disease
Post-translational modifications (PTMs) of alpha-synuclein (α-syn) can alter protein aggregation propensity to affect α-syn oligomer and fibril formation. The inflammatory response in Parkinson’s disease (PD) is mediated by microglia, astrocytes, T cells, B cells, macrophages, and neutrophils, which respond to α-syn aggregates in an attempt to clear synucleinopathy and restore brain homeostasis. This review focuses on the effects of PTMs on α-syn aggregation and cell-specific immune responses to α-syn aggregates in the context of PD.
- 26 October 2023
- Published by Open Exploration Publishing
- Vol. 3 (5) , 281-298
Open AccessThe effects of post-translational modifications on alpha-synuclein aggregation and immune cell activation in Parkinson’s disease
Post-translational modifications (PTMs) of alpha-synuclein (α-syn) can alter protein aggregation propensity to affect α-syn oligomer and fibril formation. The inflammatory response in Parkinson’s disease (PD) is mediated by microglia, astrocytes, T cells, B cells, macrophages, and neutrophils, which respond to α-syn aggregates in an attempt to clear synucleinopathy and restore brain homeostasis. This review focuses on the effects of PTMs on α-syn aggregation and cell-specific immune responses to α-syn aggregates in the context of PD.